Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | TOP1 | P11387 | 2/20 | 0.44 |
| ▸ | HRAS | P01112 | 9/20 | 0.44 |
| ▸ | ESR1 | P03372 | 9/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.41 |
| ▸ | EP300 | Q09472 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23728614 | 0.98 | HDAC1 (0.62) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL25198378 | 0.91 | HDAC1 (0.58) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL25204974 | 0.90 | HDAC1 (0.57) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL23745114 | 0.89 | HDAC1 (0.60) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL23728692 | 0.87 | HDAC1 (0.55) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL30125647 | 0.87 | HDAC1 (0.59) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL30125594 | 0.87 | HDAC1 (0.59) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL23728729 | 0.87 | HDAC1 (0.55) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL28984114 | 0.87 | HDAC1 (0.55) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL28984148 | 0.87 | HDAC1 (0.55) | HDAC1HDAC2HDAC8TOP1HRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |